Building reputation is a long-term endeavour yet as pharma moves away from a traditional B2B model to embrace patients, it is becoming a crucial success factor - Magazine Article - PharmaTimes
by Hugh Gosling
https://www.pharmatimes.com/magazine/2016/july_2016/staying_powerIn the wake of a sharp decline in sales of its blockbuster arthritis drug, Remicade, Merck & Co - known as MSD in the UK - is to offer the NHS discounts and rebates amounting to £48 million on £191 million sales, announced medical affairs
by Hugh Gosling
https://www.pharmatimes.com/news/updated_remicade_price_cut_will_save_nhs_millions,_says_merck_972072Rare diseases are starting to gain the recognition they deserve but with thousands of conditions and small populations, what do patients need and how can pharma help? - Magazine Article - PharmaTimes
by Hugh Gosling
https://www.pharmatimes.com/magazine/2016/april_2016/time_to_think_rareThe largest study of the genetics of testicular germ cell tumours has uncovered four new genetic variants associated with increased risk of testicular cancer – the most common cancer in young men. - News - PharmaTimes
by Hugh Gosling
https://www.pharmatimes.com/news/testing_could_identify_men_with_10-fold_risk_of_testicular_cancer_972067In June, 300 melanoma stakeholders will meet to discuss ways to improve patient care – but what marks this ordinary-sounding event out is that 200 attendees have the disease themselves and it is being entirely organised by a single patient -
by Hugh Gosling
https://www.pharmatimes.com/magazine/2016/may_2016/smartpeople_the_ride_of_your_lifeWith some of the world's biggest biologics teetering on the edge of the patent cliff, biosimilars are big business. Yet, with the market still in its infancy, it's not as easy as you might think to get these cheap biologics to the patients that need
by Hugh Gosling
https://www.pharmatimes.com/magazine/2016/july_2016/same_differencePharma-sponsored medical education has always been about much more than just education, yet with greater transparency, changing learning styles and increased influence of expert patients, what does the future hold for pharma's wider interactions
by Hugh Gosling
https://www.pharmatimes.com/magazine/2016/september/higher_educationThe world’s largest public-private partnership in life sciences, the Innovative Medicines Initiative (IMI), has launched two new ‘calls for proposals’, offering stakeholders from a variety of sectors the opportunity to take part in
by Hugh Gosling
https://www.pharmatimes.com/news/imi_to_focus_on_ebola,_childhood_cancers,_neurological_disorders_and_eye_disease_972303In an increasingly competitive market where patient-centricity is key, enhancing customer experience to improve loyalty could be pharma's next big step forward - Magazine Article - PharmaTimes
by Hugh Gosling
https://www.pharmatimes.com/magazine/2017/januaryfebruary/through_thick_and_thinCommunity pharmacists must work together to fight government plans to cut community pharmacy funding, a group of 400 pharmacists were told yesterday. - News - PharmaTimes
by Hugh Gosling
https://www.pharmatimes.com/news/anger_at_uk_governments_profoundly_stupid_plans_for_community_pharmacy_1020381
